Autologous hematopoietic stem cell transplantation (AHSCT) is a topic of intense interest among patients. To explain briefly again: Autologous hematopoietic stem cell transplantation (AHSCT) is not about replacement or repair of nerve tissue. This possibility
Continue reading
I would have very much wished not to have to write about this complex of topics anymore – but the current situation makes the topic of vaccination against COVID19 very topical again – and the
Continue reading
The pandemic and the discussions about vaccinating MS patients against COVID19 have shown the need for a common European approach regarding recommendations for vaccinating MS sufferers. Therefore, after the last ECTRIMS Congress in 2020, representatives
Continue reading
How long should immunotherapy for MS be continued? When can therapy be stopped? These are questions that not only concern MS patients but also many neurologists. Of course, one can take the position that long-lasting
Continue reading This year, the ECTRIMS Congress was again held virtually due to the pandemic. While this was a pity, as large international congresses thrive on the personal exchange between doctors and scientists, there was still plenty
Continue reading
Siponimod (Mayzent®) is a newly approved medication for the treatment of active secondary progressive multiple sclerosis. Like Fingolimod (Gilenya®), which is produced by the same manufacturer, Siponimod belongs to the class of so-called S1P receptor
Continue reading
In addition to the study data from Ofatumumab, which I had already reported on (see DocBlog post from September 2019), another new study program was presented at ECTRIMS 2019 in Stockholm. It is the so-called
Continue reading The new MS drug Siponimod, the further development of Fingolimod (Gilenya®), was recently approved by the Food and Drug Administration (FDA) in the USA and has been available there for some time for MS patients
Continue readingLymphocyte levels also play an important role in monitoring the active substance Fingolimod (Gilenya). However, the considerations here are quite different from those for Dimethyl fumarate (Tecfidera – Lymphocyte levels in clinical practice from March
Continue reading
Presentations of clinical trials for new MS drugs take up a large space at the AAN. It must be said somewhat restrictively that real news is rare at this point. Essentially, evaluations of subgroup analyses
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
